Special Issue

Association of *Helicobacter* pylori with Gastric Cancer

Message from the Guest Editors

With more than 1 million new cases worldwide in 2020. gastric cancer represents the 5th most common cancer and the 4th most common cause of cancer-related death. Although gastric cancer is a very heterogeneous malignant disease, infection with *Helicobacter pylori* still represents the major risk factor for its development. This is mainly due to the ability of the bacterium to manipulate the host's immune response and alter epithelial cell homeostasis. Therefore, the study of the molecular mechanisms by which H. pylori induces gastric pathology is extremely important to understand gastric cancer development and identify novel therapeutic strategies to prevent it. We are pleased to invite you to contribute to the Special Issue "Association" of Helicobacter pylori with Gastric Cancer". In this Special Issue, we will focus on the identification of the mechanisms of infection, alterations of immune and epithelial cell responses, as well as changes in microbiota induced by infection to better understand the contribution of *H. pylori* infection to gastric carcinogenesis. Original research articles and reviews are welcome.

Guest Editors

Prof. Dr. Markus Gerhard

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany

Dr. Raquel Mejias-Luque

Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/108687

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

